Background: Antiretroviral therapy (ART) suppresses HIV-1 progression, but does not eliminate residual viral production of the reservoirs that perpetuate the infection, and constitute the limiting factor for HIV-1 cure. Previous data suggest that IFNα controls HIV-1 replication in patients without ART and decreases proviral DNA in peripheral CD4+ T cells. However, we ignore whether IFNα affects the replication-competent HIV-1 reservoir in vivo.
Methods: This open, prospective study included 21 HIV-1 infected ART-suppressed (HIV-RNA<25copies/ml) and HCV-coinfected patients (HCV-RNA>10,000IU/L). Ten patients (IFN group) were treated with pegilated IFNα-2a, pegIFN (180μg/sc/week), and RBV (800-1200mg/d); 11 subjects (control group) did not receive treatment. The replication-competent reservoir was determined by quantitative viral outgrowth assay, at days 0 and 28, and reported as infectious units per million of cells (IUPM). Proviral DNA and cell-associated HIV RNA were quantified by droplet digital PCR, ddPCR, between days 0 and 28 of the study. mRNA expression of APOBEC3G, TRIM5α, TRIM22 and BST2 was measured by qPCR. All parameters were analyzed in peripheral CD4+ T cells.
Results: Subjects’ characteristics are summarized in table 1.
Although IUPM did not significantly change between d0 and d28 in any group, pegIFN/RBV administration caused a significant increase in IUPM data dispersion (Levene test, p=0.05), not observed in the control group. These data suggest that pegIFN/RBV perturbs the replication-competent reservoir in peripheral CD4+ T cells.
Longitudinally, we did not observe significant differences in cell-associated HIV-1 DNA copies, neither at d9 nor d28.
Median [IQR] cell-associated HIV RNA decreased significantly in the IFN group (d0: 0.92[0.26-3.29]; d28: 0.25[0.02-0.96]), whereas did not change in the control group (d0: 0.1287[0.07-1.45]; d28: 0.13[0.05-0.42]) (Wilcoxon signed rank test, p=0.0488 and p=0.1934, respectively), suggesting an inhibitory effect of IFN on HIV expression.
APOBEC3G, TRIM5α, TRIM22 and BST2 expression was significantly up-regulated at d9 and d28 in the IFN group, and remained stable in the control group.
Conclusions: PegIFN/RBV perturbs the replication-competent reservoir in peripheral CD4+ T cells and decreases cell-associated HIV-1 RNA, probably through the inhibition of HIV transcription by TRIM22. However, after 28 days of treatment no significant decrease was observed in replication-competent or in proviral DNA reservoir.